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Abstract 
Background: Pseudomonas aeruginosa is an important hospital infection agent causing morbidity and 
mortality with the ability to gain resistance to many antimicrobials. The objective of this study was to 
determine the sensitivity profiles of nosocomial P. aeruginosa isolates in Denizli, Turkey.  
Methods: A total 120 P. aeruginosa strains which were isolated from specimens sent to the microbiology 
laboratory between January 2015 and December 2015 were investigated. Antimicrobial resistance was 
determined by agar disc diffusion method using Mueller-Hinton agar according to Clinical and Laboratory 
Standards Institute recommendations.  
Results: With respect to sensitivity pattern, the most sensitive antimicrobials were  Amikacin, colistin, 
tobramisin, netilmicin and gentamicin  and the resistance rates were detected as 97%, 96%, 92%, 90%, 83%, 
respectively over 120 P. aeruginosa strains. The sensitivity rates for the other antimicrobials were 56% for 
Piperacilin and 54% for Tazobactam. P. aeruginosa strains 62 (52%) isolates showed multiple antimicrobial 
resistance to 13 antimicrobials 
Conclusion: To prevent the spread of the resistant bacteria, it is critically important to have strict 
antimicrobial policies while surveillance programmes for multidrug resistant organisms and infection 
control procedures need to be implemented. In the meantime, it is desirable that the antimicrobial 
susceptibility pattern of bacterial pathogens like P. aeruginosa in specialized clinical units to be 
continuously monitored and the results readily made available to clinicians so as to minimize the 
development of resistance. 
 





Known for many years to be a cause of serious wound and surgical infections, but often regarded 
as a secondary or opportunistic invader rather than a cause of primary infection in healthy tissues, 
Pseudomonas aeruginosa has now clearly emerged as a major nosocomial pathogen in 
immunocompromised and debilitated patients, as well as in cystic fibrosis patients (Pier & Ramphal, 
2005). P. aeruginosa develops resistance to many antimicrobials and sometimes the sensitivity 
status can change during treatment. In particular, development of resistance is observed with the 
use of specific antimicrobial and resistant strains can be transmitted from patient to patient (Aloush 
et al., 2006). Multiple antimicrobial resistance (MAR) problems arise because of the combination 
of resistance against various antimicrobials used in therapy and cross resistance development 
between antimicrobials.  
P. aeruginosa shows intrinsic and acquired resistance to many structurally unrelated 
antimicrobials, and previous exposure to antimicrobials often leads to multidrug-resistant P. 
aeruginosa strains (Mouton et al., 1993; Ciofu et al., 1994). When P. aeruginosa strains are resistant 
to antimicrobials, they increase the length of hospital stay and the cost of treatment (Kang et al., 
2005). Increasing resistance through the use of false antibacterial agents presents serious 
problems in the treatment of infections (Mittal et al., 2009). Antimicrobial susceptibility data of P. 
aeruginosa is limited in Turkey (Berktaş et al., 2011 Er et al., 2015).  Because of these facts, it is of 
crucial importance to isolate and identify the offending strain in order for appropriate antimicrobial 
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therapy to be initiated. The objective of this study was therefore, to determine the characteristics 
and patterns of antimicrobial resistance among isolates of P. aeruginosa recovered from clinical 
specimens in Denizli, Turkey. 
 
Materials and Methods 
 
Culture and Identification  
This study was carried out in the Department of Microbiology, Denizli State Hospital, a centrally 
located medical centre in the Denizli city, between January 2015 and December 2015. Samples were 
collected from the hospitalized patients in different clinic parts of the hospital. Samples were taken 
from various sources like urine, broncho-alveolar lavage and tracheal aspirates. 
The samples were streaked on nutrient agar plates and the plates were incubated at 370C 
for 24 hours as described by Cheesborough (1985). Then the characteristic suspected single 
colonies were subjected to Gram’s staining and then sub-cultured in MacConkey agar and blood 
agar. The pure isolates of Pseudomonas aeruginosa were transferred to 1% nutrient agar slant and 
stored in the refrigerator at 40C. P. aeruginosa was identified by biochemical test (sugar 
fermentation test) and biochemical tests were performed following the methods described in 
MacFadden (2000). Motility test of the isolated P. aeruginosa was performed following the method 
described by Cheesbrough (1985). 
 
Microbiological analyses and antimicrobial susceptibility testing  
P. aeruginosa was confirmed by the Vitek2 automated microbiology system (bioMérieux, Marcy 
l’Etoile, France). P. aeruginosa (ATCC 27853) was used as the quality control strain. The 
antimicrobials used were selected according to the 2004 National Committee for Clinical 
Laboratory Standard (NCCLS) guidelines: amikacin,   colistin, tobramycin, netilmicin, gentamicin, 
aztreonam, cefepime, ceftazidime, levofloxacin, ciprofloxacin, imipenem, meropenem, tigecycline, 
piperacillin, piperacillin/tazobactam, tetracycline and sulfamethazol/trimetroprim.  
 
Antibiogram pattern of P. aeruginosa
Antimicrobial resistance was determined by an agar disc diffusion test (Bauer et al., 1966) using 
Mueller-Hinton agar (Difco) according to Clinical and Laboratory Standards Institute (CLSI) 
recommendations (CLSI, 2005). Seventeen different antimicrobials were used. For antimicrobial 
resistance determination, the isolates were grown in Luria-Bertani (LB) broth until the turbidity 
equal to the 0.5 McFarland standard (approximately 108cfu/ml). Cultures were swabbed on to the 
Mueller–Hinton agar and all isolates were tested against. Amikacin  (AN, 30µg/ml), Colistin (CS, 
10µg/ml), Tobramycin (TM 10µg/ml), Netilmisin (NET, 10µg/ml ) Gentamicin (GEN, 10µg/ml), 
Aztreonam (ATM, 30µg/ml), Cefepime (FEP, 30µg/ml), Ceftazidime (CAZ, 10µg/ml), Levofloxacin 
(LEV, 5µg/ml), Ciprofloxacin (CIP, 5µg/ml), Imipenem (IPM,10µg/ml), Meropenem (MEM, 10µg/ml), 
Tigecycline (TGC,15µg/ml), Piperacillin (PIP,30µg/ml), Tazobactam/ piperacillin (TZP,30µg/ml), 
Tetracycline (TE, 30µg/ml), Sulfamethaxol/trimetroprim (SXT, 25µg/ml). The isolates grown in 
inoculation were evaluated as resistant and the others were evaluated as susceptible. The antibiotic 
discs were dispensed sufficiently separated from each other so as to avoid overlapping of inhibition 
zones. The plates were incubated at 37°C, and the diameters of the inhibition zones were measured 
after 18 hr. All susceptibility tests were carried out in duplicate and were repeated twice if 
discordant results had been obtained.  
 
Multiple Antimicrobial Resistance Index 
For all isolates, we calculated the MAR index values (a/b, where “a” represents the number of 
antimicrobials the isolate was resistant to; and “b” represents the total number of antimicrobials 
the isolate tested against). A MAR index value ≥ 0.2 is observed when isolates are exposed to high 
risk sources of human or animal contamination, where antimicrobials use is common; in contrast a 
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MAR index value <or = 0.2 observed when antimicrobials are seldom or never used (Krumperman, 




A total of 120 isolates of P. aeruginosa were collected from January 2015 to December 2015 from 
different patients. With respect to sensitivity pattern, the most sensitive antimicrobials were 
Amikacin, colistin, tobramisin, netilmicin, gentamycin and the resistance rates were detected as 
97%, 96%, 92%, 90%, and 83%, respectively. For the other antimicrobials, the sensitivity rates of P. 
aeruginosa were in the following order: Piperacilin and Tazobactam were recorded 56% and 54% 
respectively. 
 
Table1. Antimicrobial susceptibility pattern of Pseudomonas isolated from clinical samples  
Antimicrobial Sensitivity Resistance Intermediate 
Amikacin 116(97%) 4(3%) 0(0%) 
Colistin 115 (96%) 5 (4%) 0 (0%) 
Tobramycin 110 (92%) 3 (3%) 7 (5%) 
Netilmicin 108(90%) 7 (6%) 5(4%) 
Gentamicin 99(83%) 12 (10%) 9(8%) 
Aztreonam 87 (73%) 27 (23%) 6 (5%) 
Cefepime 87 (73%) 11 (9%) 22 (18%) 
Ceftazidime 85 (71%) 26 (22%) 9 (8%) 
Levofloxacin 74 (62%) 44 (37%) 2 (1%) 
Ciprofloxacin 73 (61%) 40 (33%) 7 (6%) 
Imipenem 73(61%) 47(39%) 0 (0%) 
Meropenem 69 (57.5%) 29 (24.2%) 26 (22%) 
Tigecycline 70 (58%) 49 (41%) 1 (1%) 
Piperacillin 67 (56%) 33 (28%) 20 (17%) 
Tozabactam/Piperacillin 65 (54.2%) 29 (24.2%) 26 (22%) 
Tetracycline 53 (44.2%) 67 (56%) 0 (0%) 
Sulfamethaxol/Trimethoprim 8 (7%) 112 (93%) 0 (0%) 
 
Out of the 120 P. aeruginosa strains 62 (52%) isolates showed Multiple Antibiotic Resistance (MAR) 
four to thirteen antimicrobials. The results were given Table2. The MAR indices ranged from 0.06 
to 0.76 isl. 
 






Multiple Antimicrobial Resistance Index  
 
Urine 38 0.06 (10 isl), 0.12(5isl), 0.18(4isl), 0.24(6isl), 0.29 (4isl), 0.35(2isl), 0.41 
(1isl), 0.49(1isl),  0.53(1isl) 0.58(1isl), 0.65(1isl) 0.76(1isl), 0.70 (1isl)  
Blood 22 0.06 (5isl), 0.12 (2isl), 0.18 (2isl), 0.24 (3isl), 0.29(3isl), 0.35(1isl), 
0.41(2isl), 0.53 (2isl), 0.70 (2isl) 
Abscess 14 0.06 (1 isl), 0.12 (1isl), 0.18 (5isl), 0.24 (4isl), 0.29 (1isl), 0.65 (1isl) 
0.76(1isl) 
Tracheal aspirate 37 0.06 (3isl), 0.12 (2isl), 0.18 (4isl), 0.24 (6isl), 0.29 (2isl), 0.35 (4isl), 0.41 
(1isl), 0.47 (5isl), 0.59 (4isl), 0.65 (3isl) 0.70 (3isl) 
Ear  2 0.12 (1isl), 0.06 (1isl) 
Pleural fluid 2 0.06 (1 isl),  0.18(1isl) 
Cerebrospinal fluid 1 0.65 (1isl) 
Mucus  4 0.06 (1isl), 0.35 (1isl), 0.47 (1isl), 0.23(1isl) 
 
Discussion   
 
Our results were similar to those of Jamasbi (2008) who reported sensitivity to Amikacin of 97%. 
However other studies have reported lower rate of sensitivity (Sharma et al., 2010; Picao et al. 2008; 
Behera et al., 2008; Hocquet et al., 2007).   An increased sensitivity of P. aeruginosa to Colistin was 
also seen in this study.  Our results were similar to Kumar et al (2014). Tobramycin has a narrow 
spectrum of activity, but it is often used to eliminate P. aeruginosa in patients with cystic fibrosis 
(Hamed & Deponnett, 2017). This aminoglycoside antimicrobial is commonly used to treat different 
Gram-negative bacteria (Bulitta et al., 2015) and has been reported to have good clinical outcome 
(Gonzalez & Spencer, 1998). Sensitivity to Tobramycin was seen in 92% isolates in our study, while 
relatively lower rates of sensitivity have been observed in other studies elsewhere (Obritisch et al., 
2004; Javiya et al. 2008; Franco et al., 2010). Sensitivity rate to aminoglycosides (gentamicin, 
netilmicin, amikac) in our study was high. Gentamicin has been used with excellent results in the 
treatment of sepsis due to Pseudomonas spp., in burn patients (Stone, 1966). Strateva et al. (2007) 
in Bulgaria reported higher resistance to P. Aeruginosa to aminoglycosides while Fadeyi et al., 
(2005) Nigeria reported relatively lower resistance levels. 
Sensitivity rate of Aztreonam was showed in 73%. Some researchers have reported 
Aztreonam sensitivity rate to P. aeruginosa  in clinical samples (Gultekin et al., 2004; Durmaz- Çetin 
et al.,  2004; Ersoz et al., 2004; Eksi et al., 2007;  Kurtoglu et al., 2008; Gayyurhan et al., 2008; 
Tuncoglu et al., 2009). Cefepime is one of the few antimicrobials described to have constant 
antipseudomonal activity over the years, although publications on cefepime resistance are growing 
in number in recent years (Eksi et al., 2007; Gayyurhan et al., 2008; Pakoz et al., 2011; Ece et al.,2014; 
Kotwal et al.,2014). Our results were similar to Eksi et al (2007) who also reported sensitivity to 
Cefepime was 74.5%.  
Some researchers have reported ceftazidime sensitivity rate to P. aeruginosa  in clinical 
samples (Yapar et al., 2000; Ayyıldiz et al., 2000; Demirci et al.,2001; Cesur et al.,2002; Al-Jasser & 
Elkhizzi., 2004; Gultekin et al., 2004; Durmaz- Cetin et al.,  2004;  Ersoz et al., 2004; Ciftci et al., 2005; 
Yücel et al.,2006; Eksi et al., 2007; Gayyurhan et al.,2008; Kurtoglu et al., 2008; Afifi et al., 2013). 
Levofloxacin sensitivity rate to P. aeruginosa in clinical samples have been reported in a number of 
studies (Pakoz et al., 2011; Sen et al., 2014).  Among the quinolones, Levofloxacin, a broad spectrum 
antimicrobial quinolones, is found to be effective against a variety of the clinical isolates, especially 
Enterococcus spp. and Pseudomonas aeruginosa (Fuchs et al., 1996; Hans et al., 1999). 
Only 69 (57.5%) isolates were susceptible to meropenem. Meropenem sensitivity rate to P. 
aeruginosa  in clinical samples has been reported by other authors (Fidan et al., 2005; Gales et al., 
2006; Gayyurhan et al.,2008; Somily et al., 2012; Afifi et al., 2013; Ece et al., 2014; Sen et al., 2014; 
Yayan et al., 2015).  We found that 61% isolates were sensitive to Ciprofloxacin in our study, similar 
to other studies (Sharma et al., 2010; Javiya et al., 2008; Gokale & Metgud, 2012). However, lower 
sensitivity rates have been reported by Franco et al. (2010) and Prakash & Saxen (2013). 
Carbapenems are the drugs of choice for many infections caused by gram positive and gram 
negative bacteria (Nicolau 2008; Shah, 2008). Sensitivity to Imipenem was observed in 61% of 
isolates in our study. Much lower rates have been observed by others (Franco et al., 2010; Picao et 
al., 2008; Behera et al., 2008) while higher rate of sensitivity have been  reported by Javiya et al. 
(2008) and by Hocquet et al. (2007). 
  Our rate of tigecycline sensitivity was 58%. Similar sensitivity pattern has been reported 
elsewhere (Somily et al., 2012; Chaudhary et al., 2013). Sensitivity rate to P. aeruginosa to piperacillin 
found in our study are similar to others (Andrade et al., 2003; Gultekin et al., 2004; Al-Tawfig., 2007; 
Berktas et al., 2011; Yayan et al., 2015). The Piperacillin/Tazobactam combination was effective in 
only about half of the isolates which is comparable to that of Javiya et al. (2008), while higher 
sensitivity was reported by Hocquet et al. (2007). The sensitivity pattern of tetracycline and 
trimethoprim observed in our study has been reported by other researchers elsewhere (Eksi et al., 
2007; Gayyurhan et al., 2008; Ullah et al.,2009; Rifaioglu et al., 2009; Sen et al.,2014; Toroglu et 
al.,2013; Sen et al.,2014 ). Tetracycline is a bacteriostatic antimicrobial and used to select mutants 
of multidrug resistance (Alonso et al., 1999). 
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The MAR indices give an indirect suggestion of the probable source(s) of the organism. The 
MAR indices in this work were greater than 0.20, this confirms the report of Olayinka et al. (2004) 
that the MAR index greater than 0.20 indicates that the organisms must have been originated from 
an environment where antimicrobials are often used (Olayinka et al., 2004). Thus, the result of the 
MAR index in this work can be interpreted that these pathogens might have been originated from 
where these antimicrobials are used. The multidrug resistance of P. aeruginosa from the hospital 
was 11.10% which confirms the report of Hota et al. (2009) that outbreaks of multidrug-resistant P. 
aeruginosa colonization or infection can occur in urology wards, a burn unit, haematology/oncology 
units, and adult and neonatal critical care units and that various medical devices and environmental 
reservoirs can be implicated in the outbreaks of the pathogen. 
To prevent the spread of the resistant bacteria, it is critically important to have strict 
antimicrobial policies while surveillance programmes for multidrug resistant organisms and 
infection control procedures need to be implemented. In the meantime, it is desirable that the 
antimicrobial susceptibility pattern of bacterial pathogens like P. aeruginosa in specialized clinical 
units to be continuously monitored and the results readily made available to clinicians so as to 
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